Longitude Capital is a healthcare-focused venture capital firm specializing in venture growth investments in biotechnology, medical technology, and health solutions companies. The firm invests in both privately held and publicly traded companies across clinical and commercial stages.
35% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 6 prior). Average disclosed round size is $81.5M (across 77 rounds with reported amounts).
Portfolio
68
Fund Size
$585M
Top Stage
Series B
Last 12 Mo
2
Team
Juliet Bakker
Managing Director
Tim Qi
Venture Partner
Trudy Vanhove
Venture Partner
Teresa Cabreros
Director of Operations & Facilities
Zack Ely
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
85 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
 Ventaris Surgical | Series A | $30M | Jan 2026 |
 Helicore | Series A | $65M | Jan 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 Fire1 | Unknown | $120M | Jan 2025 |
 Alentis Therapeutics | Series D | $181.4M | Nov 2024 |
| AAlentis | Series D | $181.4M | Nov 2024 |
 Alpha-9 Oncology | Series C | $175M | Oct 2024 |
 Endogenex | Series C | $88M | Jun 2024 |
| NNalu | Series E | $65M | Mar 2024 |
 Cohere Health | Series C | $50M | Feb 2024 |
 OrsoBio | Series B | $67M | Jan 2024 |
| OrsoBio | Series A | $60M | Nov 2023 |
 Quanta Therapeutics | Series D | $50.7M | May 2023 |
 Cortica | Growth | $75M | Apr 2023 |
| Fire1 | Unknown | $25M | Mar 2023 |
 Lassen Therapeutics | Series B | $85M | Jan 2023 |
| OrsoBio | Series A | $60M | Jan 2023 |
| AAlpha-9 Theranostics | Series B | $75M | Dec 2022 |
 Opna Bio | Series A | $38M | Nov 2022 |
 Rivus Pharmaceuticals | Series B | $132M | Sep 2022 |
 IntelyCare | Series C | $115M | Apr 2022 |
 Somatus | Series E | $325M | Feb 2022 |
| AAvenge Bio | Series A | — | Jan 2022 |
| RRivus Pharma | Series B | $132M | Jan 2022 |
Page 1 of 4
Top Co-Investors
RA Capital Management13 shared
Frazier Healthcare Partners13 shared
Omega Funds11 shared
OrbiMed10 shared
Novo Capital8 shared
Frazier Life Sciences7 shared
Enavate Sciences7 shared
Polaris Partners7 shared
Sofinnova Partners6 shared
Deerfield6 shared
Samsara BioCapital5 shared
New Leaf Venture Partners5 shared
Flare Capital Partners5 shared
Medicxi5 shared
Bain Capital Life Sciences5 shared
Endeavour Vision5 shared
Wellington Management5 shared
Adams Street Partners5 shared
Rock Springs Capital5 shared
Gilde Healthcare5 shared
Last updated: 7 September 2026